News. 09/12/14

Procuritas Capital Investors V LP invests in Fidelix Oy

Guernsey

Private equity fund Procuritas Capital Investors V, LP acquires majority of Finnish Fidelix Oy.

Procuritas Capital Investors V, LP advised by the eldest Private Equity firm in the Nordic region today, Procuritas, are pleased to announce the acquisition of a majority ownership of the Finnish building management company Fidelix Oy. The investment is part of Procuritas’ strategy to support the growth of upcoming market leaders in Nordic technology industries.

“The ownership structure changes will give Fidelix Oy excellent possibilities for further development”, says Fidelix Oy CEO Jussi Rantanen. “The new owners value the professional workforce and the technology developed by Fidelix, and see them as a basis for reaching new markets. Our systems give the possibility for the use of environmental protecting technology by optimizing real estate energy use and supporting the use of renewable energy such as geothermal heating and solar energy.”
“Even though the construction business, as a cyclical industry, has been in a challenging situation, we have been growing our employee base in Finland annually. Through the new growth opportunities, we expect to grow our employee base further both in Finland and abroad.” – says Rantanen.

Mr. James Orrick, Director at Procuritas Capital Investors V GP Limited, summarized the possibilities of Fidelix Oy:

“The company is well managed and its products represent the cutting edge technology of its field. Fidelix’s success in Finland and Sweden, the leading countries in environmental technology, shows the potential it has also in new markets.”

For further information, please contract:

Jussi Rantanen, CEO, Fidelix Oy
tel. +358 40 078 7842
James Orrick, Procuritas Capital Investors V, GP
tel. +44 1481 730 988
Hans Wikse, Procuritas Partners AB, as advisor to PCI V
tel. +46 8 506 14300

Fidelix Oy is a Finnish company founded in 2002, which, with its subsidiaries, Suomen Kiinteistöenergia Oy and Fidelix Sverige AB, focuses on building management and security systems, as well as care products. Fidelix’s revenue and profitability has been growing annually, being 18,6 M€ last fiscal year ending September 2014 . The group growth during the last fiscal year was 19%.

Procuritas Capital Investors V, LP (“PCI V”) is a private equity fund focusing on mid-sized companies in the Nordic Region. PCI V has ample liquidity and is interested in acquiring attractive companies with sales ranging from €20-150 million. PCI V is advised by Procuritas Partners AB and Procuritas Partners GmbH. Procuritas Partners AB is a Scandinavian private equity house specialized in initiating, structuring, and financing management buyouts (MBO). Procuritas, founded in 1986, has been a pioneer in introducing the concept of MBOs in the Nordic region.

More news.

09/04/24

Polarn O. Pyret appoints Sara Sjöberg as new CEO

Procuritas Capital Investors VI (”Procuritas”), the Swedish private equity firm dedicated to growing Nordic mid-market enterprises, is delighted to announce the appointment of Sara Sjöberg as the forthcoming Chief Executive Officer for its portfolio company, Polarn O. Pyret, the iconic Swedish childrenswear brand. Sara Sjöberg steps into this role with a wealth of experience from...

 08/04/24

Humana to acquire Team Olivia’s Norwegian operation

Team Olivia, a leading care service provider in the Nordics has entered into an agreement to sell its Norwegian operations, Team Olivia Norge AS, to Human Care Holding AS (“Humana”). The Transaction is subject to approval by the Norwegian competition authority and is expected to be completed during the second quarter of 2024. Team Olivia,...

 28/02/24

Procuritas partners up with Precision BioLogic

Procuritas Capital Investors VII (Procuritas) acquires Precision BioLogic (PBI) and subsidiary (Affinity Biologicals), fast-growing niche leaders in hemostasis diagnostics and research. PBI has in recent years launched a number of successful diagnostics products and is active in a growing market, supported by long-term trends such as ageing population, emerging new therapies, and increased access to...